SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
15,945Targets
453Trials
85Drugs
7Datasets
8,004Sources
221,721Claims
232,882Evidence
73,172Hypotheses
DRUGphase2antibody

taldefgrobep alfa

Brand names: BHV-2000

Mechanism

Anti-myostatin antibody. Inhibits myostatin to promote muscle growth and prevent atrophy.

Related claims (1)

TypePredicateConfSource
drug targetTaldefgrobep alfa selectively binds to myostatin and competitively inhibits other ligands that signal through the activin II receptor.59%39408601

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center